The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer.

Clicks: 39
ID: 283398
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
BACKGROUND This study aimed to evaluate the effect of dose reduction of CDK4/6 inhibitors on survival outcomes in postmenopausal patients with HR+ HER2-negative metastatic breast cancer (mBC). METHODS A retrospective cohort study was conducted involving 164 postmenopausal patients with HR+ HER2-negative mBC who received CDK4/6 inhibitors between 2021 and 2024. Clinical parameters were systematically analyzed. Progression-free survival (PFS) and overall survival (OS) were evaluated based on dose reduction status. Survival outcomes were estimated using the Kaplan-Meier method, and independent prognostic factors were identified through multivariate Cox regression analysis. RESULTS The median age was 61 years, with a median follow-up of 23.5 months. The median PFS was 23.3 months, while median OS was not reached. Dose reduction occurred in 45 patients (27%), who exhibited significantly worse survival (PFS HR: 1.67, 95% CI: 1.02-2.72, p = 0.042; OS HR: 2.54, 95% CI: 1.34-4.83, p = 0.004). Dose reduction and liver metastases were independent risk factors for shorter PFS and OS, while treatment in later lines was associated with shorter PFS. CONCLUSION Dose reductions in CDK4/6 inhibitors were associated with worse survival outcomes in postmenopausal HR+ HER2- mBC patients. Future biomarker-driven studies are needed to guide personalized dose adjustments and optimize treatment efficacy.
Reference Key
ceylan2025the Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors F. Ceylan; Safa Can Efil; Didem Sener; Ateş Kutay Tenekeci; Burak Bilgin; Şebnem Yücel; Eren Göktuğ Ceylan; M. Hızal; M. Şendur; M. Akıncı; Öznur Bal; Bulent Yalcin
Journal expert review of anticancer therapy
Year 2025
DOI
10.1080/14737140.2025.2490289
URL
https://www.semanticscholar.org/paper/4b2df1d0e740c34c174dec563137101e252ef82e
Keywords
Inhibitors survival effect reduction metastatic dose breast postmenopausal cdk4/6 her2-negative cancer.

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.